Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 03 2024 - 4:01PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
gene editing company focused on revolutionizing medicine with
CRISPR-based therapies, today announced that on December 1, 2024,
it awarded an inducement grant to one new employee under Intellia’s
2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock
units (“RSUs”) for 3,521 shares of Intellia’s common stock, with
one-third of such RSUs vesting on December 1, 2025, 2026, and
2027.
All equity vesting is subject to the employee’s continued
service as an employee of, or other service provider to, Intellia
through the applicable vesting dates.
The above-described award was granted outside of Intellia’s
stockholder-approved equity incentive plans pursuant to Intellia’s
2024 Inducement Plan, which was adopted by the board of directors
in June 2024. The award was approved by Intellia’s compensation
committee as a material inducement to entering into employment with
Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading
clinical-stage gene editing company focused on revolutionizing
medicine with CRISPR-based therapies. The company’s in
vivo programs use CRISPR to enable precise editing of
disease-causing genes directly inside the human body.
Intellia’s ex vivo programs use CRISPR to engineer human
cells outside the body for the treatment of cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its people, is helping set the
standard for a new class of medicine. To harness the full potential
of gene editing, Intellia continues to expand the capabilities of
its CRISPR-based platform with novel editing and delivery
technologies. Learn more at intelliatx.com and follow us
@intelliatx.
Intellia Contacts:
Investors:
Lina LiSenior Director, Investor Relations and Corporate
Communicationslina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jan 2024 to Jan 2025